Compare DHF & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHF | CNTB |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 140.4M |
| IPO Year | 1998 | 2020 |
| Metric | DHF | CNTB |
|---|---|---|
| Price | $2.21 | $0.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.71 |
| AVG Volume (30 Days) | 529.4K | ★ 599.6K |
| Earning Date | 01-01-0001 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | $7,473.67 |
| Revenue Next Year | N/A | $240.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.12 | $0.55 |
| 52 Week High | $2.57 | $3.82 |
| Indicator | DHF | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 45.76 | 36.76 |
| Support Level | $2.16 | N/A |
| Resistance Level | $2.23 | $2.62 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 12.67 | 33.75 |
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.